Express Pharma

Gilead gets US FDA nod for Trodelvy to treat metastatic triple-negative breast cancer

Trodelvy significantly reduced the risk of death by 49 per cent compared with single-agent chemotherapy in the Phase 3 ASCENT Study

0 397